EP is a community where members connect through shared life experiences-- like MS--and so much more. You are not defined by any one thing, so be your true self and find others just like you at
Experience Project.
Posted: Thu Dec 14, 2006 9:03 am Post subject: Tysabri Copay
I'm curious to know how much of a copay people are being charged for Tysabri. I remember when it originally came out people were being charged anywhere from $0 to $90 per infusion.
Joined: May 26, 2004 Posts: 1359 Location: London, ON, Canada
Posted: Fri Dec 29, 2006 9:38 am Post subject: Re: Co-pay
torres wrote:
I pay $246.99 a month. It's a scary bill but BCBS pays 90% of the Tysabri infusion which is $5,076.26 a month so I can't complain.
Diane
Wow, somebody is making a few bucks on this procedure!! The wholesale cost of Tysabri from Biogen is about $ 2300.00. I guess everyone wants to get their slice of the pie.
At 13 infusions required a year, that means a cost of almost $ 66,000 per patient.....for a drug that's efficacy is questionable at least
At 13 infusions required a year, that means a cost of almost $ 66,000 per patient
Another truth, at $2184.62 per vial (wholesale) x's 13 infusions per year, that's equivalent to $28,400.06 per year, with most ins. co's covering same as an outpatient procedure. It's the infusion centers are price gouging the ins. co's and the patients. And when most fall in line with what is reasonable to charge, don't be surprised if the ones doing the price gouging now are left in the dust with lost patients, lost dr. referrals, lost ins. payments, etc.
Take care ladies and Happy New Year to you both!
Lauren _________________ Feel free to visit my Blog and leave me a comment, I'd love to hear from you!
Natalizumab reduced the rate of clinical relapse at one year by 68 percent
I don't understand why they're quoting one year data in a two year trial. Could you please tell us the number and percent of people on Tysabri who had a relapse in the two year trial and give us the same data for the placebo group?
Personally I find that particular statistic you (and Biogen) repeatedly quote meaningless.
Joined: May 26, 2004 Posts: 1359 Location: London, ON, Canada
Posted: Sat Dec 30, 2006 11:10 pm Post subject: Re: Hi Diane and Katie!
Quote:
Truth is,Tysabri's efficacy is proven 68% superior.
I guess you can use numbers to try and prove almost anything. That 68% is what Biogen says is a relative reduction of relapse rate over the placebo used in the trials.....not 68% superior!
Quote:
[/color][color=blue]Another truth, at $2184.62 per vial (wholesale) x's 13 infusions per year, that's equivalent to $28,400.06 per year, with most ins. co's covering same as an outpatient procedure. It's the infusion centers are price gouging the ins. co's and the patients. And when most fall in line with what is reasonable to charge, don't be surprised if the ones doing the price gouging now are left in the dust with lost patients, lost dr. referrals, lost ins. payments, etc.
Do you honestly think that any infusion center is only going to charge the patient the wholesale cost of the drug??!! These are the very infusion centers that Biogen is approving to administer Tysabri. Biogen set the tone for these centers when they jacked up the price of the drug by about 22% before the second FDA approval. With the risks associated with this drug and all the precautions that must be taken, these centers are going to charge as much as they can. No wonder we are hearing about insurance companies balking at approving this treatment.
At least we know who is going to have a very Happy New Year....Biogen and the infusion centers as they march to bank with their ludicrous profits on this medication!
Joined: Aug 14, 2006 Posts: 103 Location: So. Calif.
Posted: Sun Dec 31, 2006 3:10 pm Post subject: Hello Sharon...
Personally, I wasn't quoting Biogen, I was quoting the findings of the New England Journal of Medicine...you can review them for yourself to answer your own questions - it's called "Due Diligence":
which lists other links for you to research for yourself.
Links Listed there - Comment on:
N Engl J Med.2006 Jun 1;354(22):2387-9; author reply 2387-9.
N Engl J Med. 2006 Mar 2;354(9):899-910.
N Engl J Med. 2006 Mar 2;354(9):911-23.
N Engl J Med. 2006 Mar 2;354(9):924-33.
N Engl J Med. 2006 Mar 2;354(9):965-7.
Natalizumab for relapsing multiple sclerosis.
Have fun ya'll. Byeeeee......,
Lauren _________________ Feel free to visit my Blog and leave me a comment, I'd love to hear from you!
Joined: May 26, 2004 Posts: 1359 Location: London, ON, Canada
Posted: Mon Jan 01, 2007 12:08 am Post subject: Re: Hello Sharon...
msladyinca wrote:
[color=blue]Personally, I wasn't quoting Biogen, I was quoting the findings of the New England Journal of Medicine...you can review them for yourself to answer your own questions - it's called "Due Diligence":
And where do you think the NEJ obtains their information...from the data supplied by Biogen. If you believe everything that Biogen has told us about Tysabri then fine. I just don't have the same trust in that company than you have. Remember, this is the same company that refused to provide the trial data to Anita Smith's family legal team that is suing Biogen. It took a court order from a judge to force Biogen to do this. He severely chastised Biogen for being so stubborn and cold hearted in refusing at first to provide this data.
I'm betting Biogen eventually settles this case out of court to avoid what the lawyers will make public in court.
You cannot post new topics in this forum You cannot reply to topics in this forum You cannot edit your posts in this forum You cannot delete your posts in this forum You cannot vote in polls in this forum
We encourage you to also visit our Multiple Sclerosis story and support community on Experience Project.
Experience Project is a vast and powerful community where people connect anonymously through life experiences. It's made by the same people who built This is MS,
on the premise that no one life experience-- like having MS-- defines a person. It now covers over 2 million life stories. Find and share yours!